行情

SYRS

SYRS

Syros医药
NASDAQ

实时行情|Nasdaq Last Sale

0.7696
-0.1293
-14.38%
盘后: 0.8080 +0.0384 +4.99% 17:56 05/16 EDT
开盘
0.9231
昨收
0.8989
最高
0.9300
最低
0.7600
成交量
107.97万
成交额
0
52周最高
7.03
52周最低
0.7600
市值
4,777.91万
市盈率(TTM)
-0.5571
分时
5日
1月
3月
1年
5年
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 11小时前
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 12小时前
BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share $0.40
reuters.com · 12小时前
Syros Pharmaceuticals: Q1 Earnings Insights
  Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 12小时前
Syros Pharmaceuticals Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $5.47M Beat $4.92M Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 73.91 percent decrease over losses of $(0.23) per share
Benzinga · 13小时前
Syros Pharmaceuticals GAAP EPS of -$0.40 beats by $0.07, revenue of $5.47M beats by $0.55M
Syros Pharmaceuticals press release (NASDAQ:SYRS): Q1 GAAP EPS of -$0.40 beats by $0.07. Revenue of $5.47M (+13.3% Y/Y) beats by $0.55M. Cash, cash equivalents and marketable securities as of March
Seekingalpha · 13小时前
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 15小时前
Syros Pharmaceuticals Q1 2022 Earnings Preview
Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.47 (-104.3% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 3天前
更多
暂无数据
了解SYRS最新的财务预测,通过SYRS每股收益,每股净资产,每股现金流等数据分析Syros医药近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

12.50%强力推荐
87.50%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测SYRS价格均价为15.86,最高价位23.00,最低价为9.00。
最高23.00
均价15.86
最低9.00
现价0.7696
EPS
实际EPS
预期EPS
-0.38-0.29-0.19-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 115
机构持股: 5,342.03万
持股比例: 86.05%
总股本: 6,208.30万
类型机构数股数
增持
31
273.28万
建仓
11
49.53万
减持
32
133.84万
平仓
22
83.80万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.23%
制药与医学研究
+1.02%
高管信息
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Nancy Simonian
Chief Financial Officer
Jason Haas
Chief Scientific Officer
Eric Olson
Other
Conley Chee
Other
David Roth
Other
Kristin Stephens
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
Deborah Dunsire
Independent Director
S. Gail Eckhardt
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
暂无数据
暂无数据
SYRS 简况
Syros Pharmaceuticals Inc是一家生物制药公司。该公司致力于重新保护小分子控制基因表达的能力。该公司致力于开发单一基因突变导致的癌症和疾病的治疗方法,也称为单基因疾病,并建立基因控制药物的临床阶段管道。其主要候选产品包括SY-1425、SY-2101和SY-5609。其SY-1425是一种选择性视黄酸受体α(RARα),正在与氮胞苷联合评估,以用于治疗急性髓细胞性白血病(AML)。其SY-2101,一种新型口服形式的三氧化二砷(ATO),正在开发用于治疗急性髓细胞白血病。其SY-5609是一种选择性和有效的口服细胞周期蛋白依赖性激酶7(CDK7)抑制剂,正在针对部分晚期实体瘤患者进行剂量递增部分评估。

微牛提供Syros Pharmaceuticals Inc(NASDAQ-SYRS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SYRS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SYRS股票基本功能。